Get started
VERTEX PHARMACEUTICALS INCVERTEX PHARMACEUTICALS INCVERTEX PHARMACEUTICALS INC

VERTEX PHARMACEUTICALS INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

VX1 trade ideas

VRTX Beginning!Fundamental & Chart Not for investment advice, personal notes only Chart: identified key area of support, concerning current H&S pattern, potential downside to next support indicate 17% drop. CMF shows weakness, spending a lot of times in the negatives. So far trend line remains intact, neckline of H&S shows no particular bearish inclination Fundamentals: Core product in strong growth, In January 26, 2021, VRTX announced that it received FDA approval for the use of Trikafta with children ages 6-11 with CF and certain mutations. In January 28, 2021, VRTX announced that it received FDA clearance for its type-1 diabetes investigational medicine and will enter the phase ½ clinical trial. Powerful toppling and bottom line growth, Net income has grown 229% from 2019 to September 2020. Currently seeking acquisition opportunities Let's wait and see
NASDAQ:VRTXLong
by jerryz73001
2
VRTX Gap Fill Play - Bullish- Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. - Target Price: $292.00 by CreditSuisse Oct 29, 2020 with multiple buy ratings by different analysts - Recent Drop from failed study of VX-814 for patients with ALPHA-1 ANTITRYPSIN DEFICIENCY, but still one more study going in same target area and fundamentals of other revenue makers intact. - Price entering the gap from that day's drop. - Trends of more insider buying since the drop and stock buy backs. Signaling that the stock is undervalued. - Bull flagging right under the gap. Key Level: $232.41 Price Target: 269.93 ATR: $6.60 Play: Bullish Gap Fill Buy the Dip under the key level to scale in Use $232.41 as inflection point. Look for breakout with increased volume Price Target: 270 Under $224 will invalidate
NASDAQ:VRTXLong
by Pr0diJ